ストックスクリーナーアプリを入手
2.08
1.96%
0.04
アフターアワーズ：
2.08
Armata Pharmaceuticals Inc (ARMP) 最新ニュース
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 203.3% - MarketBeat
10 Best Healthcare Stocks to Invest In (February 2025) - Securities.io
Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GlaxoSmithKline, AstraZeneca - The Globe and Mail
Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.
Armata Pharmaceuticals (STU:TG1N) PS Ratio : (As of Jan. 14, 2025) - GuruFocus.com
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat
Armata Pharmaceuticals Announces $35 Million Secured Credit Agre - GuruFocus.com
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 125.9% - MarketBeat
Ampliphi Biosciences (NYSEAMERICAN:APHB) Announces Positive Results from Phase 2 Tailwind Study - Defense World
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns “Buy” Rating from HC Wainwright - Defense World
Armata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study - Yahoo Finance
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given Buy Rating at HC Wainwright - MarketBeat
Armata Pharmaceuticals Reports Positive Phase 2 Study Results - TipRanks
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PR Newswire
ARMP Stock Touches 52-Week Low at $1.98 Amid Market Challenges - Investing.com
Suparna Mishra Sarkar - Los Angeles Times
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - The Eastern Progress Online
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - The Eastern Progress Online
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - The Eastern Progress Online
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit - GuruFocus.com
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - GuruFocus.com
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates - MSN
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting – Company AnnouncementFT.com - Financial Times
Armata Pharmaceuticals FY2024 EPS Raised by HC Wainwright - MarketBeat
Armata Pharmaceuticals Extends Credit Agreement and CMO Departs - TipRanks
HC Wainwright Reiterates “Buy” Rating for Armata Pharmaceuticals (NYSEAMERICAN:ARMP) - Defense World
Armata Pharmaceuticals Reports $3M Revenue, Advances Key Clinical Trials in Q3 | ARMP Stock News - StockTitan
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given "Buy" Rating at HC Wainwright - MarketBeat
Armata Pharmaceuticals Announces Structural Biology Publication - PR Newswire
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Decline in Short Interest - MarketBeat
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 2.2%Should You Sell? - MarketBeat
Armata Pharmaceuticals VP Richard Rychlik Departs with Benefits - TipRanks
Armata Pharmaceuticals announces executive departure - Investing.com
Arkema S.A. (OTCMKTS:ARKAY) Sees Large Growth in Short Interest - MarketBeat
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Confronting Oropouche: a new stage for Cuban science - Radio Cadena Agramonte
Alto Neuroscience's Market Cap Drops To US$358m Leaving Insiders With Losses - Simply Wall St
American Century Companies Inc. Purchases 8,841 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily
ANRO’s latest rating updates from top analysts. - Knox Daily
ARKO Corp. (ARKO) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Art’s-Way Manufacturing (NASDAQ:ARTW) Now Covered by StockNews.com - Defense World
Dimensional Fund Advisors LP Has $193.14 Million Position in Archrock, Inc. (NYSE:AROC) - Defense World
Your Safety First: What You Need to Know About Bionpharma’s Urgent Atovaquone Recall - MyChesCo
Building Materials Stocks Q2 Results: Benchmarking Armstrong World (NYSE:AWI) - Yahoo Finance
Aurora Biosynthetics launch set to revolutionise RNA Therapeutics - Manufactures Monthly
Amplia Therapeutics’ Drug Fast-Tracked by FDA - TipRanks
Atovaquone Oral Suspension Recall Issued Due to Bacterial Contamination Risks - AboutLawsuits.com
Burgundy Asset Management Ltd. Purchases 17,075 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 - GuruFocus.com
New player in RNA manufacturing: Aurora Biosynthetics launches in Australia - Australian Manufacturing
1.03%
大文字化:
|
ボリューム (24 時間):